Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Psilo Scientific
Burnaby, British Columbia, Canada
- Ownership
- Private
- Development stage
- Other
01
Overview
Psilo Scientific develops standardized botanical psilocybin and psilocin drug candidates (PEX010, PEX020, PEX030) in Phase 1/2 clinical trials for mental health indications; authorized Phase 2 trial in Sweden for PEX010 as of June 2025.[2]
- Therapeutic areas
- Psychiatry
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
PharmAla BiotechCybin TherapeuticsMagdalena Biosciences (JV with Jaguar Health)Linkoping University
Beyond the preview
Go deeper on Psilo Scientific.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Psilo Scientific.